Biomega Group (‘Biomega’), a leading biosciences company producing high-quality ingredients for the health and nutrition sectors, has released a new whitepaper discussing the positive contribution salmon peptides could have on minimising the risk factors associated with cardiovascular disease.
Each year, cardiovascular disease (‘CVD’) accounts for 3.9 million deaths in Europe and is the primary cause of death in the region according to the European Heart Network. With dietary factors the largest contribution to the risk of CVD mortality, maintaining a healthy diet and active lifestyle is one of the best ways to combat two of the greatest medical risks associated with the disease; high systolic blood pressure and bad cholesterol.
Bjorn Liaset, Director of R&D at Biomega said: “There is increasing science-backed evidence available that shows how functional food ingredients and supplements can help reduce the risk of CVD and coronary heart disease by lowering what’s known as the ‘bad’ low-density lipoprotein (‘LDL’) cholesterol, while simultaneously improving the ‘good’ high-density lipoprotein (‘HDL’) cholesterol.
“Our whitepaper explores how niacin, which is found at high levels in Biomega salmon peptides, can elevate good cholesterol to promote general heart wellness in humans. In addition, we also discuss how the anti-atherosclerotic properties of salmon peptides can aid in cardiovascular protection.”
Entitled, ‘Understanding Salmon Peptides and Cardiovascular Health’, the whitepaper is the first in a series of releases from Biomega explaining the benefits of salmon peptides in human and animal health. The whitepaper, which is available to download for free, can be accessed by emailing email@example.com.